We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Instruments Automate PCR Diagnostic Applications

By LabMedica International staff writers
Posted on 27 Jan 2014
Two new diagnostic instruments, which recently have been certified for marketing in Europe (CE marked), will bring an unprecedented level of automation and efficiency to laboratories that process large and very large numbers of specimens on a daily basis.

The Roche Molecular Diagnostics (Pleasanton, CA, USA) Cobas 6800/8800 system has automated PCR technology for virology, blood screening, HPV (human papillomavirus and CT/NG (Chlamydia trachomatis and Neisseria gonorrhea) testing. More...
The system comes in two models—large (6800) and very-large (8800) throughput capacity—and was developed to deliver increased automation and throughput, with minimal user intervention and improved quality control.

The instruments are equipped with an onboard refrigerator to allow for significantly longer reagent storage capacity and less loading and unloading of reagents. The instrument design provides greater ergonomics in terms of the user-instrument interface, reducing the number of required user interactions. Once the instrument is loaded, the system can run continuously for eight or four hours for the Cobas 6800 and Cobas 8800 system, respectively. This translates into a throughput of 300 and 1000 results in eight hours, respectively. Once the instrument begins processing samples, the first 96 results can be reported within three-and-a-quarter hours. Thereafter, the Cobas 6800 and 8800 instruments provide up to 96 results every 90 or 30 minutes, respectively.

This level of efficiency was obtained by completely automating the processing of primary and secondary tubes all the way through to the patient sample result for any combination of three different tests at the same time. This parallel sample to result process is accomplished using a universal sample preparation, PCR profile, and reagent setup process.

During the first six months of the systems' CE launch, several assays will be available for virology labs (HIV, HCV, HBV, and CMV) and for blood screening labs (combined HIV/HCV/HBV, WNV, and combined Parvovirus B19/HAV). In the near future, the system will support additional assays including HPV, CT/NG, and a utility channel for user-defined applications.

Related Links:
Roche Molecular Diagnostics



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Automatic CLIA Analyzer
Shine i6000
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.